IP Library Granted Patent US 9,233,141
Granted Patent B2
US 9,233,141 · App. 14/104,591 · Granted Jan 12, 2016

Modified polynucleotides for the production of proteins associated with blood and lymphatic disorders

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,233,141
App. No.
14/104,591
Granted
Jan 12, 2016
Kind
B2
Abstract

The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.

Claims (9)

1. A composition comprising at least one mRNA, wherein said at least one mRNA comprises

a first region of linked nucleosides, said first region encoding SEQ ID NO 909, and wherein said first region comprises a coding region having at least 80% identity to SEQ ID NO: 9244.

2. The composition of claim 1 , wherein the at least one mRNA comprises a poly-A tail.

3. The composition of claim 2 , wherein the at least one mRNA comprises a 5′ cap structure.

4. The composition of claim 2 , wherein the at least one mRNA is purified.

5. The composition of claim 1 , comprising a pharmaceutically acceptable excipient.

6. The composition of claim 5 , wherein the pharmaceutically acceptable excipient is selected from the group consisting of a solvent, aqueous solvent, nonaqueous solvent, dispersion media, diluent, dispersion, suspension aid, surface active agent, isotonic agent, thickening or emulsifying agent, preservative, lipid, lipidoids liposome, lipid nanoparticle, core-shell nanoparticles, polymer, lipoplex, peptide, protein, cell, hyaluronidase, and mixtures thereof.

7. The composition of claim 1 , wherein the coding region of the mRNA is selected from the group consisting of SEQ ID NOs: 9244, 9243, 9264, 9280, 9305, 9308, 9316, 9318, and 9327.

8. A method of producing Factor X, in a cell, tissue, or organism comprising contacting said cell, tissue, or organism with the at least one mRNA of claim 1 .

Assignments (3)
SECURITY INTEREST Recorded Nov 19, 2025
From: MODERNATX, INC.
To: ARES CAPITAL CORPORATION, AS AGENT
Reel/Frame 073634/0354 →
CHANGE OF NAME Recorded Mar 28, 2018
From: MODERNA THERAPEUTICS, INC.
To: MODERNATX, INC.
Reel/Frame 045755/0844 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 21, 2014
From: BANCEL, STEPHANE; CHAKRABORTY, TIRTHA; DE FOUGEROLLES, ANTONIN; WHORISKEY, SUSAN; ELBASHIR, SAYDA M.
To: MODERNA THERAPEUTICS, INC.
Reel/Frame 032270/0028 →